Ben Sasse Joins Rev Med’s Pancreatic Cancer Drug Trial with Gratitude
Ben Sasse, a former U.S. senator from Nebraska, has recently begun treatment for metastatic pancreatic cancer. Faced with a dire prognosis, Sasse made a proactive choice to seek experimental options for his condition. He enrolled in a clinical trial for the drug daraxonrasib, developed by Revolution Medicines (Rev Med). His determination stems from the belief that aggressive intervention could extend his life beyond the initial estimate of just three to four months.
Clinical Trial Overview
Currently, Sasse is participating in the RASolute 302 trial, which is assessing daraxonrasib as a first-line therapy. This trial has generated significant interest in the pancreatic cancer community. Preliminary Phase 3 results indicate that patients receiving daraxonrasib show a survival rate of 13.2 months, compared to 6.7 months for those treated with conventional chemotherapy.
Potential Impact on Pancreatic Cancer Treatment
- Drug Name: Daraxonrasib
- Company: Revolution Medicines
- Trial Name: RASolute 302
- Survival Improvement: 13.2 months versus 6.7 months
Results from this trial suggest that patients who are treated with daraxonrasib at an earlier stage may experience even more significant benefits. Sasse himself noted that his condition has improved since starting the treatment, stating that it has exceeded his expectations regarding both quantity and quality of life.
Symptoms and Diagnosis
Sasse’s journey began with severe and unusual back pain, characterized by shooting sensations and front abdominal cramping. Initial blood tests revealed no troubling results, prompting further scans. A phone call from his doctor revealed the gravity of his situation: numerous tumors and a significant mass in his pancreas. Following this diagnosis in December, he prioritized gathering information and exploring treatment options for his cancer.
Finding the Right Treatment
To expedite treatment, Sasse sought out renowned institutions such as MD Anderson Cancer Center and Memorial Sloan Kettering. Consultation with Dr. Eileen O’Reilly, noted as a leading expert in pancreatic cancer, affirmed his decision to participate in a clinical trial. The findings at these institutions highlighted the lack of efficacy in traditional chemotherapy for his condition, thus reinforcing his resolve to seek new avenues of treatment.
Experiences During Treatment
While on daraxonrasib, Sasse has experienced various effects, both positive and challenging. Reports of substantial pain reduction, along with a drop in CA 19-9 levels—a common biomarker for pancreatic cancer—offer hope. Initially starting at over 8,000, his levels fell significantly to 374. This drop indicates a potential response to the treatment, along with a reported 60% reduction in tumor volume.
Gratitude for Research and Care
Reflecting on his experiences, Sasse expressed deep gratitude for the medical professionals leading the trial. He acknowledged the collective effort in advancing pancreatic cancer treatment, stating his appreciation for the exceptional care he has received. The ability to spend time with his family while pursuing this groundbreaking treatment has made the journey more manageable.
As breakthroughs in cancer treatment continue to emerge, Sasse’s experience exemplifies the potential for revolutionary therapies to change prognoses for patients diagnosed with challenging conditions like pancreatic cancer.
